Applying these new technologies, several biotech

companies are engaged in preclinical and early clinical research on HSV-2 and chlamydia vaccines, but need support to cross the valley of death from preclinical research to proof of concept in humans. Following this, reliable advanced animal models such as NHPs should be developed for comparative testing of vaccines/adjuvant systems in order and take the most promising candidates into clinic phase and design clinical trials. The use of human challenges can significantly increase the efficiency of research and reduce both the time and the cost of vaccine development. Crucial information on the BGB324 research buy pathogenesis of chlamydia, gonorrhea and trichomonas, and on the LDN-193189 in vitro efficacy of candidate vaccines

could be obtained from a small number of human subjects with challenge studies. In these trials, immune responses can be measured closely prior to and following infection or vaccination, providing important information regarding the identification of biomarkers and correlates of protection, and selection of the most promising vaccine candidates for testing in large Phase III clinical trials. This approach can be used only for infectious diseases that can be fully treated, which is the case with STIs that are curable by an antibiotic treatment. Decision to conduct such studies should be based on the evaluation of the probability and magnitude of risks of harm for the volunteers, in a well-defined scientific and ethical framework [52] and [53]. This approach has been employed in testing vaccines for cholera, malaria, influenza, typhoid fever, and more recently, gonorrhea, to study the natural history of experimental infection with two well characterized strains of N. gonorrhoeae [54]. Modeling studies will have to be carried out to better define the target population of these vaccines, their potential impact on disease transmission, as well as their cost-effectiveness. Sharing lessons learned from vaccine

success stories as well as from vaccine failures may be critical to STI vaccine discovery and development. The successful development of HPV vaccine demonstrated that a vaccine can induce a better immunity than natural infection, and opens the tuclazepam way to the introduction of STI vaccination in adolescents. Useful information for the development of a vaccine against HSV-2 can be learned from vaccine against the varicella zoster herpes virus (VZV) [55]; and the recent development of a vaccine against Neisseria meningitidis group B could help in identifying candidate antigens for a gonorrhea vaccine by comparative genome analysis. Much can also be learned from the analysis of clinical trials of herpes and chlamydia vaccines that failed to show protection, and from studies on HIV vaccines that provided crucial information in mucosal immunity.